Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Результаты клинического исследования препарата Инфибета (II–III фаза). Рекомендации по переводу пациентов c рассеянным склерозом на биоаналоги
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Гусев Е.И., Демина Т.Л., Бойко А.Н. Рассеянный склероз. М., 1997.
2. Paty DW, Hartung HP, Ebers GC et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999; 6 (Suppl. 1): 1–35.
3. Gaines AR, Varrichio F. Interferon beta-1b injection site reactions and necrosis. Multiple Sclerosis 1998; 4: 70–3.
4. IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61.
5. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer-Verlag, London, 1996; p. 230–1.
6. Munschauer FE, Kinkel RP. Managing side effects of Interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Therap 1997; 19: 883–93.
7. Lyseng-Williamson KA. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. K.Lyseng-Williamson, D.Murdoch. Drugs 2005; 65 (9): 1295–312.
8. Kappos L. New aspects in treatment of multiple sclerosis with interferon beta–1b. J Neurology 2004; 251 (4): 1.
9. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon-beta-1b in the treatment of MS; final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85.
10. Lublin FD, Whitaker JN, Eidelman BH et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12–8.
11. Walther EU, Dang T, Hohlfeld R. Management of side effects of beta-interferon therapy in MS. Int MS J 1999; 5: 65–70.
12. Bayas A, Reickmann P. Managing the Adverse Effects of Interferon-b Therapy in Multiple Sclerosis. Drug Safety 2000; 22: 149–59.
13. Durelli L, Ogerro A, Verdun E et al. Does high-dose interferon-beta-1b improve clinical response in more severely disabled multiple sclerosis patients? J Neurol Sci 2000; 178: 37–41.
14. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurology Neurosurgery and Psychiatry 2005; 76: 469–75.
15. Patten SB, Metz LM. Interferon beta-1a and depression in relapsing-remitting MS: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7 (4): 243–8.
16. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4): 655–61.
17. Filippi M, Tortorella C, Bozzali M. Normal appearing white matter changes in multiple sclerosis. The contribution of magnetic resonance techniques. Multiple Sclerosis 1999; 5: 273–82.
18. Rovaris M, Agosta F, Sormani MP et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003; 126 (10): 2323–32.
19. Martinelli BF, Rovaris M, Comi G, Filippi M. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Mult Scler 2004; 10 (4): 341–7.
20. Castelijns J, Barkhof F. Magnetic resonance (MR) imaging as a marker for multiple sclerosis. Biomed Pharmacother 1999; 53 (8): 351–7.
21. Fazekas F, Barkhof F, Filippi M et al. The contribution of magnetic resonance imaging to the diagnosis multiple sclerosis. Neurology 1999; 53: 448–56.
22. Kesselring J, Lassmann H. Pathogenesis Multiple sclerosis. Ed. J.Kesselring. Cambridge University Press 1997; p. 54–62.
23. Zivadinov R, Cox JL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007; 79: 449–74.
24. The North Fmerican Study Group on Interferon beta-1b in Secondary-Progressive MS. Interferonbeta-1binsecondaryprogressiveMS. Neurology 2004; 63: 1788–95.
25. Гусев Е.И., Бойко А.Н. Рассеянный склероз: от изучения иммунопатогенеза к новым методам лечения. М., 2001.
2. Paty DW, Hartung HP, Ebers GC et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines. Eur J Neurol 1999; 6 (Suppl. 1): 1–35.
3. Gaines AR, Varrichio F. Interferon beta-1b injection site reactions and necrosis. Multiple Sclerosis 1998; 4: 70–3.
4. IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61.
5. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. Multiple sclerosis, Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer-Verlag, London, 1996; p. 230–1.
6. Munschauer FE, Kinkel RP. Managing side effects of Interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Therap 1997; 19: 883–93.
7. Lyseng-Williamson KA. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. K.Lyseng-Williamson, D.Murdoch. Drugs 2005; 65 (9): 1295–312.
8. Kappos L. New aspects in treatment of multiple sclerosis with interferon beta–1b. J Neurology 2004; 251 (4): 1.
9. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon-beta-1b in the treatment of MS; final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85.
10. Lublin FD, Whitaker JN, Eidelman BH et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996; 46: 12–8.
11. Walther EU, Dang T, Hohlfeld R. Management of side effects of beta-interferon therapy in MS. Int MS J 1999; 5: 65–70.
12. Bayas A, Reickmann P. Managing the Adverse Effects of Interferon-b Therapy in Multiple Sclerosis. Drug Safety 2000; 22: 149–59.
13. Durelli L, Ogerro A, Verdun E et al. Does high-dose interferon-beta-1b improve clinical response in more severely disabled multiple sclerosis patients? J Neurol Sci 2000; 178: 37–41.
14. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurology Neurosurgery and Psychiatry 2005; 76: 469–75.
15. Patten SB, Metz LM. Interferon beta-1a and depression in relapsing-remitting MS: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001; 7 (4): 243–8.
16. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4): 655–61.
17. Filippi M, Tortorella C, Bozzali M. Normal appearing white matter changes in multiple sclerosis. The contribution of magnetic resonance techniques. Multiple Sclerosis 1999; 5: 273–82.
18. Rovaris M, Agosta F, Sormani MP et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 2003; 126 (10): 2323–32.
19. Martinelli BF, Rovaris M, Comi G, Filippi M. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Mult Scler 2004; 10 (4): 341–7.
20. Castelijns J, Barkhof F. Magnetic resonance (MR) imaging as a marker for multiple sclerosis. Biomed Pharmacother 1999; 53 (8): 351–7.
21. Fazekas F, Barkhof F, Filippi M et al. The contribution of magnetic resonance imaging to the diagnosis multiple sclerosis. Neurology 1999; 53: 448–56.
22. Kesselring J, Lassmann H. Pathogenesis Multiple sclerosis. Ed. J.Kesselring. Cambridge University Press 1997; p. 54–62.
23. Zivadinov R, Cox JL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007; 79: 449–74.
24. The North Fmerican Study Group on Interferon beta-1b in Secondary-Progressive MS. Interferonbeta-1binsecondaryprogressiveMS. Neurology 2004; 63: 1788–95.
25. Гусев Е.И., Бойко А.Н. Рассеянный склероз: от изучения иммунопатогенеза к новым методам лечения. М., 2001.
Авторы
Е.В.Попова1, А.Н.Бойко1, А.В.Васильев3, М.В.Давыдовская1, И.А.Завалишин3, С.В.Котов2, М.В.Кротенкова3, Н.В.Хачанова1, С.Н.Шаранова1, С.Г.Щур1, Т.И.Якушина2
1. Московский городской центр рассеянного склероза (ГКБ №11);
2. ГУ Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского;
3. Научный центр неврологии РАМН
1. Московский городской центр рассеянного склероза (ГКБ №11);
2. ГУ Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского;
3. Научный центр неврологии РАМН
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.